UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma

Fu,Wen; Lei,Xiangxiang; Lu,Qiliang; Zhang,Ji; Guo,Jinhui; Zhao,Jie; Tong,Xiangmin; Hu,Xiaoge

doi:10.3892/ijo.2023.5500

UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma

Authors:
- Wen Fu
- Xiangxiang Lei
- Qiliang Lu
- Ji Zhang
- Jinhui Guo
- Jie Zhao
- Xiangmin Tong
- Xiaoge Hu
View Affiliations

Affiliations: Qingdao Medical College, Qingdao University, Qingdao, Shandong 266071, P.R. China, The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, P.R. China
Published online on: March 9, 2023 https://doi.org/10.3892/ijo.2023.5500
Article Number: 52
Copyright: © Fu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a noteworthy malignant carcinoma with an unsatisfactory prognosis attributed to late diagnosis. Ubiquitin‑conjugating enzyme E2K (UBE2K) has been found to serve important roles in a number of diseases. However, its function and the exact molecular mechanism of UBE2K in PDAC remain to be elucidated. The present study discovered that UBE2K was expressed at high levels and indicated the poor prognosis of patients with PDAC. Following this, the CCK‑8, colony formation, and sphere formation assays showed that UBE2K promoted proliferation and the stemness phenotype of PDAC cells in vitro. Evidence from subcutaneous tumor‑bearing nude mice experiments further confirmed that UBE2K enhanced PDAC cell tumorigenesis in vivo. Additionally, the present study demonstrated that insulin‑like growth factor 2 RNA binding protein 3 (IGF2BP3) functioned as an RNA‑binding protein to increase UBE2K expression by enhancing the RNA stability of UBE2K. The knockdown or overexpression of IGF2BP3 could attenuate the change in cells growth induced by the overexpression or knockdown of UBE2K. In summary, the findings indicated the oncogenic roles of UBE2K in PDAC. In addition, IGF2BP3 and UBE2K constitute a functional axis to regulate the malignant progression of PDAC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
3	Nevala-Plagemann C, Hidalgo M and Garrido-Laguna I: From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 17:108–123. 2020. View Article : Google Scholar
4	Grice GL and Nathan JA: The recognition of ubiquitinated proteins by the proteasome. Cell Mol Life Sci. 73:3497–3506. 2016. View Article : Google Scholar : PubMed/NCBI
5	Maxwell BA, Gwon Y, Mishra A, Peng J, Nakamura H, Zhang K, Kim HJ and Taylor JP: Ubiquitination is essential for recovery of cellular activities after heat shock. Science. 372:eabc35932021. View Article : Google Scholar : PubMed/NCBI
6	Salas-Lloret D and Gonzalez-Prieto R: Insights in post-translational modifications: Ubiquitin and SUMO. Int J Mol Sci. 23:32812022. View Article : Google Scholar : PubMed/NCBI
7	Swatek KN and Komander D: Ubiquitin modifications. Cell Res. 26:399–422. 2016. View Article : Google Scholar : PubMed/NCBI
8	Middleton AJ, Teyra J, Zhu J, Sidhu SS and Day CL: Identification of ubiquitin variants that inhibit the E2 ubiquitin conjugating enzyme, Ube2k. ACS Chem Biol. 16:1745–1756. 2021. View Article : Google Scholar : PubMed/NCBI
9	Middleton AJ and Day CL: The molecular basis of lysine 48 ubiquitin chain synthesis by Ube2K. Sci Rep. 5:167932015. View Article : Google Scholar : PubMed/NCBI
10	Cook BW, Lacoursiere RE and Shaw GS: Recruitment of ubiquitin within an E2 chain elongation complex. Biophys J. 118:1679–1689. 2020.
11	Song S, Kim SY, Hong YM, Jo DG, Lee JY, Shim SM, Chung CW, Seo SJ, Yoo YJ, Koh JY, et al: Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol Cell. 12:553–563. 2003. View Article : Google Scholar : PubMed/NCBI
12	de Pril R, Fischer DF, Roos RA and van Leeuwen FW: Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases. Mol Cell Neurosci. 34:10–19. 2007. View Article : Google Scholar
13	Su J, Huang P, Qin M, Lu Q, Sang X, Cai Y, Wang Y, Liu F, Wu R, Wang X, et al: Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models. Cell Death Dis. 9:10202018. View Article : Google Scholar : PubMed/NCBI
14	Tak YJ and Kang S: The E2 ubiquitin-conjugating enzyme HIP2 is a crucial regulator of quality control against mutant SOD1 proteotoxicity. Biochim Biophys Acta Mol Basis Dis. 1868:1663162022. View Article : Google Scholar
15	Wang Q, Dong Z, Su J, Huang J, Xiao P, Tian L, Chen Y, Ma L and Chen X: Ixazomib inhibits myeloma cell proliferation by targeting UBE2K. Biochem Biophys Res Commun. 549:1–7. 2021. View Article : Google Scholar : PubMed/NCBI
16	Wu J, Tian B, Yang J, Huo H, Song Z, Yu J and Gu Y: Reduction of Hip2 suppresses gastric cancer cell proliferation, migration, invasion and tumorigenesis. Transl Cancer Res. 9:774–785. 2020. View Article : Google Scholar : PubMed/NCBI
17	Coppin L, Leclerc J, Vincent A, Porchet N and Pigny P: Messenger RNA life-cycle in cancer cells: Emerging role of conventional and non-conventional RNA-Binding proteins? Int J Mol Sci. 19:6502018. View Article : Google Scholar : PubMed/NCBI
18	Mancarella C and Scotlandi K: IGF2BP3 from physiology to cancer: Novel discoveries, unsolved issues, and future perspectives. Front Cell Dev Biol. 7:3632020. View Article : Google Scholar : PubMed/NCBI
19	Zhang N, Shen Y, Li H, Chen Y, Zhang P, Lou S and Deng J: The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability. Exp Mol Med. 54:194–205. 2022. View Article : Google Scholar : PubMed/NCBI
20	Wang C, Kong F, Ma J, Miao J, Su P, Yang H, Li Q and Ma X: IGF2BP3 enhances the mRNA stability of E2F3 by interacting with LINC00958 to promote endometrial carcinoma progression. Cell Death Discov. 8:2792022. View Article : Google Scholar : PubMed/NCBI
21	Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W, Guo W, Wu X, Pu C, Hu X, et al: METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N (6)-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol Cancer. 21:602022. View Article : Google Scholar
22	Han J and Hu X: IGF2BP3stabilized SIX4 promotes the proliferation, migration, invasion and tube formation of ovarian cancer cells. Mol Med Rep. 26:2322022. View Article : Google Scholar
23	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45(W1): W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
24	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
25	Xie X, Lin J, Fan X, Zhong Y, Chen Y, Liu K, Ren Y, Chen X, Lai D, Li X, et al: LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription. Cell Death Dis. 12:2012021. View Article : Google Scholar : PubMed/NCBI
26	Wang X, Tian L, Li Y, Wang J, Yan B, Yang L, Li Q, Zhao R, Liu M, Wang P and Sun Y: RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent. J Exp Clin Cancer Res. 40:802021. View Article : Google Scholar : PubMed/NCBI
27	Wang L, Zhang S, Li H and Xu Y, Wu Q, Shen J, Li T and Xu Y: Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma. BMC Cancer. 21:8762021. View Article : Google Scholar : PubMed/NCBI
28	Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
29	Hershko A: Ubiquitin: Roles in protein modification and breakdown. Cell. 34:11–12. 1983. View Article : Google Scholar : PubMed/NCBI